Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 6 5 3
ROE
(155,671.52%) (473.47%) (355.31%) (146.27%)
ROA
30.34% 47.54% 58.47% (41.90%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
171.64% 248.32% 249.03% (223.41%)
Average Days of Receivables
2,460.67 159.41 175.25 102.13
Free Cash Flow per Share
(0.78) (1.18) (1.25) (1.20)
Free Cash Flow
(90.19) (138.51) (170.57) (186.03)
Other line items
Cash ROIC
(28.51%) (51.27%) (60.31%) (91.46%)
Accounts Receivable Turnover
0.17 0.60 1.10 0.76
Accounts Payable Turnover
0.54 0.72 0.57 0.62
Inventory Turnover
0.50 3.74 3.59 3.11
Average Days of Payables
725.77 261.98 279.79 303.77
Days of Inventory on Hand
59.71 83.81 117.60 130.73
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
265.56% 258.20% 226.25% 198.70%
Selling, General and Administrative Expense of Revenue
286.90% 238.56% 208.35% 181.79%
Share Based Compensation of Revenue
55.35% 40.23% 29.82% 21.87%
Interest Coverage
(24.15) (20.12) (19.02) (17.47)
Operating CF/Net income
(0.58) (0.82) (0.92) 1.41
Depreciation/Fixed assets
2.49 2.92 3.44 4.17
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.32 0.36 0.34 0.33
Operating CF per Share
(0.78) (1.18) (1.25) (1.20)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates